Shanghai Haohai Biological Technology Co Ltd vs China Pharma Holdings Inc.
A side-by-side look at two Chinese stocks — live quote, valuation, growth, listing venue, dual-listing and delisting status, and the WealthyTec Rank. A factual comparison for orientation, not investment advice.
| Metric | Shanghai Haohai Biological Technology Co Ltd 6826.HK · Hong Kong 16.05 HKD | China Pharma Holdings Inc. CPHI · US (ADR) 0.57 USD |
|---|---|---|
| Day change | +0.88% | -10.97% |
| Market cap | $327.7M | $24.8M |
| P/E (TTM) | — | — |
| 2y EPS CAGR | — | +8.9% |
| WealthyTec Rank | 5.1 | 2.0 |
| Rank within sector | #14 of 31 | #21 of 31 |
| Listing venue | HKEX | NYSE / NASDAQ (ADR) |
| Other listings | n/a | n/a |
| Delisting filings | None on record | None on record |
| Sector | Health Care | Health Care |
| Industry | Biotech and Pharma | Biotech and Pharma |
Of the two, Shanghai Haohai Biological Technology Co Ltd currently carries the higher WealthyTec Rank (5.1 vs 2.0). The Rank reflects past revenue, earnings and EPS trends only — not valuation, momentum, or the policy and delisting risks every China investor should weigh, and it is not a recommendation to buy, sell or hold either security. See our rank methodology.